Celebrex
The Painful surgical adhesion can be preventable taking inhibitor COX-2 Celebrex, the general spoken medicine of the arthritis, before simply and immediately after surgery, researchers of the message in Boston Hospitals Detey. Their information were published in January 25 online Annals to Surgery.
The Adhesion - a bands fabrics scar, which links together two internal surfaces of the body - a development in 55 percents in more, than 90 percents patient, being subjected to surgery, depending on type of the action. They separate normal, curing, but when fuze of the surfaces together that was not, serious pain and complications can occur. The Adhesion - a main reason of the barrier of the gut and infertility, and surgery of the repetition - often it is necessary to cut through them. Unfortunately, adhesion often returns after these operation, and there is no good way of the prevention he.
The Studies were winnowed Dr. Mark Puder and Dr. Arin Greene in Division of Surgery and Sosudistaya Program to Biologies in Boston Hospitals Detey tested inhibitors COX-2 in models animal abdominal forming the adhesion. Surgery be subjected to After, groups 6 18 mouses got or inhibitors COX-2 (Celebrex or Vioxx), not-selective inhibitors COX (such as, ibuprofen and aspirin) or for 10 days.
At 10 days, the group had an obvious abdominal adhesion. The Mouse, getting not-selective inhibitors COX had a lung reduction in adhesion, and group of the inhibitor COX-2 had a greater reduction. The most Great reduction was in mouse Celebrex, and 6 11 addressed mouses Celebrex (55%), were completely free from adhesion.
The Researchers then observed Celebrex, Vioxx, aspirin and is grouped for additional 25 days. Besides, group Celebrex had an adhesion fewest. The Estimation of the adhesion ( the measure both extent of the adhesion and difficulty of the removing he), was only 1 in group Celebrex, 5 in group Vioxx, 8 in group of the aspirin, and 11 in group.
Founded in these information, Puder prepares to install much-stated clinical trial of Celebrex on adult surgical patient. “If functioning Celebrex on folk, You could give this patient for day of abdominal surgery and 10 days following surgery,” Puder communicates.
Currently, the most commonly method of the prevention of the adhesion uses the agent of the barrier or helium to separate the abdominal surfaces and prevent them from relationship together. However, these processing can suppress the firm system, cause the infection and spoil healing.
Though this analysis looked at abdominal adhesion, Puder believes that inhibitors COX-2 also reduce adhesion after gynecologic and breast surgery, and after orthopedic and plastic surgery possible.
the inhibitors COX-2 are anti-inflammatory medicine to the best advantage heard for their use in arthritis. However, they also hold up angiogenesis, or formation blood and Celebrex also holds up fibroblast activity important on forming the scar. These three characteristics do Celebrex particularly good candidate for test, Puder reports for the first time since adhesion consists of inflammatory cell, blood and fibroblasts.
“If You stop each component of the adhesion, then during five days surface fabrics will get the safe new lining mesothelial cell,” Puder communicates. “As soon as these cells resurface area, adhesion is not formed.”
Puder And colleagues did not do to be fixed to study the adhesion. They studied the effects Celebrex in liver regeneration after damage in liver. When they went to study the liver of the mouses, they have paid attention to their own wonder that was not no adhesions, unusual finding. The Ithaca, they have solved to do the formal experiment.
THE NETWORK of Health WellPoint this week released the analysis, which interfaced the inhibitors COX-2 Vioxx, Celebrex and Bextra on raised cardiovascular risk, ” intensify the information of the other test” as two… THE CONSULTING committees in Ambience are going to to begin the meetings on medication, AP/Long (the length) of the message Island Newsday. The Analysis included record 7,232 ages patient 40 and more old, which took Vioxx, Celebrex or Bextra during at least once 18 months and record 629,245 individuals of the similar age who did not take the medication. The Analysis, what WellPoint began after Merck in late September 2004 voluntarily withdrewed Vioxx with the market on safe enxiety, included patient is written with January 2001 on June 20, 2004. The Analysis found that participants, which took Vioxx and Celebrex had 20% increased risk for heart attack and blow and that that, which took Bextra had 50% increased risk. Merck And Pfizer, what production Celebrex and Bextra, has said that such studies - what retrospective patient writing the check - not such exact as blind, clinical test operated However, Sam Nussbaum, executive WellPoint vice president and the main medical executive, said, “This - as medicine are used in real world. This - important and reliable analysis.” Nussbaum Added that though analysis provides the additional acknowledgement “exceedingly forcing direction,” WellPoint will not check the policy, which requires to get the preceding permit previously, than they Celebrex and Bextra. However, policy “could change depending on result, hearing” in inhibitor COX-2, messages AP/ Newsday. Nussbaum has Said that he has spread the results of the analysis with and Pfizer. Pfizer spokesperson Mariann Caprino has Said that company has not studied the results of the analysis or used to methodologies. Besides, review Pfizer internal test has found Celebrex and Bextra did not enlarge the cardiovascular risk. Eric Matteson, professor medicine in fission rheumatology in Clinic Mayo, convened analysis WellPoint significant, adding, “All signals are indicated in same direction…. Clear, there is degree of the risk in these medicine and doctors must more careful about assigning them.” Matteson Added, which he does not expect that is removed Celebrex or Bextra with the market (Agovino, AP/Long (the length) Island Newsday, 2/14).
Over 27 million patient in United Staff, is given Celebrex (celecoxib), which was approved USA. Food and Administration Medicine in 1998.
“Pfizer Sure of long-term cardiovascular safety Celebrex,” said Dr. Joe Feczko, president Pfizer’s worldwide development.
In the last subsidized study 1.4 million patient, that, which got Celebrex not demonstrated no increased risk warmhearted event.
“Patients, inhibitors COX-2 can be matted and must talk with their doctor,” Dr. Feczko said. “Because of its unpaid long-term safe profile and broad base of the instruction including osteoarthritis, rheumatoid arthritis and quiping pain, Celebrex - approaching alternative of the processing.”
